Psoralen / EMD Serono - LARVOL DELTA

A Retrospective Real-World Comparison of Topical Delgocitinib and Localized Cream Psoralen-Ultraviolet A in Chronic Hand Eczema. (PubMed, Dermatol Ther (Heidelb)) - "Delgocitinib and PUVA provided comparable short-term clinical efficacy in CHE, with a numerically greater DLQI reduction for delgocitinib. Proactive delgocitinib maintenance may help sustain disease control. Subtype-adapted treatment strategies could further optimize outcomes."

Journal • Real-world evidence • Retrospective data • Atopic Dermatitis • CNS Disorders • Contact Dermatitis • Dermatology • Immunology • Pain • Pruritus • Sleep Disorder

Arbuscular Mycorrhizal Consortium Alleviates Chromium(VI) Stress and Enhances Seed Phytochemicals in Psoralea corylifolia L. (PubMed, Plant Sci) - "Notably, AMF-colonized plants produced seeds with increased accumulation of key bioactive metabolites, including bakuchiol, psoralen, and isopsoralen, even at the highest Cr(VI) level...Overall, AMF consortia represent an effective, biologically grounded approach to enhance chromium tolerance, stabilize yield, and improve the medicinal value of P. corylifolia. These findings support AMF-assisted cultivation as a practical strategy for producing high-quality medicinal raw material in chromium-contaminated soils while reducing the physiological and biochemical constraints imposed by metal toxicity."

Journal

Phototherapy as skin-directed treatment for cutaneous chronic graft-versus-host disease: A case series (AAD 2026) - "Modalities included narrowband-UV-B (19 cycles), systemic psoralen-UV-A (6), and topical psoralen-UV-A (1)... Phototherapy is a safe and effective therapy for cutaneous cGVHD. Its consistent improvement across subtypes and low toxicity make it a valuable option to minimize corticosteroid and immunosuppressant exposure."

Clinical • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Dermatopathology • Graft versus Host Disease • Immunology • Lichen Planus • Pruritus

Pharmacokinetics of three pairs isomers of Caraway in Beagle dogs based on UPLC-MS/MS (PubMed, Zhongguo Zhong Yao Za Zhi) - "This study established a rapid, sensitive, and convenient ultra-high performance liquid chromatography tandem mass spectrometry(UPLC-MS/MS) method for the simultaneous determination of three pairs of isomers(psoralen and isopsoralen, bavachin and isobavachalcone, bavachromene and isobavachromene) in Beagle dog plasma after oral administration of Caraway extract, and investigated their pharmacokinetic characteristics using a non-compartmental analysis method...Bavachin exposure was the lowest, and its pharmacokinetic parameters could not be determined. This study provides a scientific basis for the clinical application and subsequent new drug research of Caraway."

Journal • PK/PD data

Clinical Use and Safety of Self-Tanner (Topical Dihydroxyacetone) in Dermatology: A Systematic Review. (PubMed, J Cutan Med Surg) - "DHA may have some use in patients with vitiligo and EPP. No studies demonstrated harm related to DHA use, though most studies were low-quality, conducted on a few humans or animals, occasionally with product concentrations over the threshold permitted by the European Commission. Unresolved safety concerns about free-radical formation require high-quality research to clarify DHA's long-term health impacts."

Journal • Review • Contact Dermatitis • Dermatitis • Dermatology • Genetic Disorders • Immunology • Metabolic Disorders • Oncology • Skin Cancer • Vitiligo

Psoralen Promotes Direct Chemical Reprogramming of Mouse Embryonic Fibroblasts into Osteoblast-like Cells. (PubMed, Pharmaceutics) - "Here, we systematically evaluated whether the natural compound psoralen (Psr) could enhance this process and explored its therapeutic potential and mechanism of action...Mechanistically, Psr co-treatment potently activated the ADCY9/cAMP/PKA/CREB pathway, and pharmacological inhibition of this pathway completely abolished the pro-osteogenic effects of Psr. Psr acts as a potent synergistic enhancer of direct chemical reprogramming, generating functional osteoblast-like cells with robust bone-regenerative capacity via activation of the ADCY9/cAMP/PKA/CREB pathway."

Journal • Preclinical

Psoralen and Isopsoralen from Psoralea corylifolia Suppress NSCLC by Dual Mechanisms: STAT3 Inhibition and ROS Modulation. (PubMed, Pharmaceuticals (Basel)) - "In a H2O2-induced oxidative stress model, pretreatment with psoralen or isopsoralen significantly reduced ROS levels in HUVECs, while increasing ROS accumulation in A549 lung cancer cells. This work identifies psoralen and isopsoralen as novel dual-function STAT3 inhibitors that exert anti-NSCLC effects through combined STAT3 suppression and context-dependent ROS modulation, and demonstrates the utility of SPR for screening bioactive natural products."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

CRMP2 inhibits metastasis formation by impairing ILF3-dependent stabilization of CXCL10 mRNA in breast cancer. (PubMed, Cell Death Dis) - "Finally, we found that psoralen interacts with CRMP2 and suppresses the development of lung metastases in breast cancer. In conclusion, our findings uncover a critical CRMP2-related mechanism behind breast tumor metastasis, and the CRMP2-ILF3-CXCL10 axis may provide a potential therapeutic strategy for controlling breast cancer metastasis."

Journal • Breast Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • CRMP • CXCL10 • IL3

Case Report: Extracorporeal photopheresis for cutaneous lupus erythematosus induces putatively atheroprotective B and T cell responses. (PubMed, Front Immunol) - "Extracorporeal photopheresis (ECP) involves the reinfusion of autologous peripheral blood lymphocytes rendered apoptotic by in vitro exposure to psoralen and ultraviolet A light...Additionally, we documented an increase in circulating regulatory T cells, which are recognized as suppressing pro-atherogenic immune responses. These findings support the translational potential of a preclinical atheroprotection model and provide a proof of concept for clinical trials evaluating ECP in autoimmune diseases associated with accelerated atherosclerosis, where achieving dual benefits, clinical improvement and reduced cardiovascular risk, may be feasible."

Journal • Atherosclerosis • Cardiovascular • Cutaneous Lupus Erythematosus • Cutaneous T-cell Lymphoma • Dyslipidemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Inflammatory Arthritis • Lupus • Lymphoma • Metabolic Disorders • Oncology • T Cell Non-Hodgkin Lymphoma • APOE

Metabolomic and Functional Evidence for Psoralen Associated with Resistance of Pepper against the Whitefly. (PubMed, J Agric Food Chem) - "Biochemical assays further indicated that psoralen inhibits key whitefly detoxification enzymes (GSTs, CarEs) and digestive enzymes (cellulase, α-amylase). These findings identify psoralen as an inducible defense metabolite contributing to pepper resistance against B. tabaci and highlight its potential for sustainable whitefly control through crop improvement or botanical insecticide development."

Journal

The Prediction of Quality Markers of Notopterygium Incisum Based on Mass Transfer Law and Network Pharmacology. (PubMed, J AOAC Int) - "In this study, mass transfer analysis, network pharmacology, and HPLC fingerprinting were integrated, combined with orthogonal partial least squares-discriminant analysis (OPLS-DA) and molecular docking. Potential Q-Markers of NI for the treatment of cardiovascular diseases were identified."

Journal • Cardiovascular • Ophthalmology

Differential analysis of free and bound phenolic compounds and its antioxidant activity of Ficus hirta Vahl. root cortex with different leaf morphotypes based on metabolomics. (PubMed, Food Chem X) - "Pearson correlation identified that psoralen and other 18 phenolic compounds were positively correlated with antioxidant activity. These findings can provide theoretical basis for the breeding of F. hirta Vahl. varieties to maximize phenol production for later development and commercial utilization."

Journal

Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of Generalized Vitiligo. (clinicaltrials.gov) - P1 | N=64 | Not yet recruiting | Sponsor: Hayat Abad Medical Complex, Peshawar | Trial completion date: May 2026 ➔ Dec 2026 | Initiation date: Dec 2025 ➔ Jun 2026 | Trial primary completion date: May 2026 ➔ Dec 2026

Trial completion date • Trial initiation date • Trial primary completion date • Dermatology • Immunology • Vitiligo

X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma (clinicaltrials.gov) - P1 | N=52 | Recruiting | Sponsor: Immunolight, LLC | N=20 ➔ 52

Enrollment change • Breast Cancer • Head and Neck Cancer • Melanoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Triple Negative Breast Cancer • BRCA • BRCA1 • ER • HER-2 • PD-L1 • PGR

pH-Responsive Psoralen Delivery System for Infected Bone Defects: Spatiotemporal Photothermal Disinfection Coupled with Osteogenesis and Osteoclast Regulation. (PubMed, Small) - "In vivo evaluation in polymicrobial (Staphylococcus aureus and Escherichia coli)-infected rat calvarial defect models demonstrates effective pathogen eradication and enhanced osteogenic differentiation. This dual-functional nanoplatform represents a promising strategy for the clinical management of infected bone defects and broadens the potential of nanomedicine in regenerative applications for infected tissues."

Journal • Infectious Disease

New mitochondrial KV1.3 conjugates are potent and specific inducers of apoptosis in cancer models. (PubMed, Biomed Pharmacother) - "This study introduces a new structural class of mitochondria-targeted KV1.3 inhibitors with enhanced solubility compared to psoralen-based analogues. The unique mechanism of action, characterized by rapid depolarization and moderate ROS dependence, underscores their potential as selective anticancer agents. These findings warrant further investigation into in vivo efficacy and potential synergy with existing therapies."

Journal • Preclinical • Oncology • Pancreatic Cancer • BCL2 • CASP3 • CASP7

Effectiveness of Oral Psoralen + UV-A (PUVA) Therapy in the Treatment of Chronic Cutaneous Graft Versus Host Disease (GVHD): A Retrospective, Observational Study Analysis from a Tertiary Care Centre. (PubMed, Indian J Hematol Blood Transfus) - "Other immunosuppressants were stopped after an average of 4.57 months in 8 patients. We hereby conclude that PUVA therapy is a much better alternative to the conventional immune suppressing agents for chronic GVHD."

Journal • Observational data • Retrospective data • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Oncology • Scleroderma • Systemic Sclerosis • Transplantation

Comprehensive studies of plasma pharmacokinetic and bone tissue distribution in rats to elucidate pharmacodynamic material basis of Psoraleae Fructus treating osteoporosis. (PubMed, J Ethnopharmacol) - "The above findings suggested that the main constituents distributed in bone tissue enhanced the osteogenic differentiation and mineralization by activating AKT/GSK-3β/β-catenin pathway, indicating them as the pharmacodynamic material basis of PF in the treatment of osteoporosis. Furthermore, this study on PK and BTD analyses of other non-main constituents was also possible to provide extremely crucial reference bases for them at multiple levels, including subsequent research, development, and application."

Journal • PK/PD data • Preclinical • Osteoporosis • Rheumatology • RUNX2

Detection of Epigenetically Important 5-Formylcytosine Modifications Using Novel Photoreactive Oligonucleotides Containing a Trioxsalen-Conjugated Guanosine. (PubMed, J Am Chem Soc) - "Herein, we designed novel photoreactive nucleosides by conjugating a psoralen (Ps) derivative, trioxsalen, to the C2' position of guanosine (GPs and GPs2) and developed photo-crosslinkable oligonucleotides (GPs-Oligo and GPs2-Oligo). In particular, GPs-Oligo demonstrated an intriguing and unique ability of photo-crosslinking with 5fC. GPs-Oligo was employed to detect 5fC using a DNA chip glass plate, which demonstrated the potential of GPs-Oligo for future investigation of the function of 5fC inside cells."

Journal

Analysis of the Proliferation-Inhibiting Active Components Against Periodontal Pathogenic Bacteria Contained in Fig Leaf Extract. (PubMed, FEMS Microbiol Lett) - "TLC and HPLC analyses revealed the presence of psoralen, bergapten, and several unidentified compounds...Known fig leaf compounds were not the main contributors to the observed effects. These findings suggest that fig leaf ethyl acetate extract may be a promising natural antibacterial agent for oral hygiene products, particularly targeting P. gingivalis, and may help prevent periodontal and related systemic diseases."

Journal • Dental Disorders • Periodontitis

Juglans regia L. attenuate Psoralea corylifolia L.-induced hepatotoxicity by regulating the Nrf2 pathway and amino acid metabolism. (PubMed, J Ethnopharmacol) - "WKs mitigated PF-induced liver injury through multiple pathways, particularly by reducing the levels of injury-causing components. Additionally, WKs activate the Nrf2/HO-1 signaling pathway and modulate amino acid metabolism."

Journal • Hepatology • Liver Failure • NQO1

A Bifunctional Antibody Conjugate for Marking the Location of DNA Binding Proteins on DNA Fibers. (PubMed, ACS Omega) - "Exposure to long-wave UV light covalently linked psoralen to the DNA...This technique denotes the location of γ-H2AX along DNA fibers following ionizing irradiation of the cells and the relationship between DSBs and γ-H2AX. Our results demonstrate that, after radiation, most γ-H2AX signals detected on DNA fibers are located at internal sites rather than at ends."

Journal

X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Immunolight, LLC | Trial completion date: Mar 2026 ➔ Mar 2029 | Trial primary completion date: Sep 2025 ➔ Sep 2028

Trial completion date • Trial primary completion date • Breast Cancer • Head and Neck Cancer • Melanoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Psoralen promotes SOCS5 to inhibit JAK/STAT3 to alleviate cartilage degeneration in knee osteoarthritis. (PubMed, Phytomedicine) - "Our findings demonstrate that psoralen is a key therapeutic component of BSQJ for KOA treatment. It alleviates cartilage degeneration by targeting SOCS5 and modulating the JAK-STAT3 pathway, thereby restoring chondrocyte metabolic homeostasis. This study provides a pharmacological basis for psoralen as a promising candidate drug for KOA."

Journal • Immunology • Osteoarthritis • Pain • Rheumatology • SOCS5 • STAT3

PD12 Narrowband ultraviolet B and psoralen plus ultraviolet A phototherapy for mycosis fungoides: a 17-year retrospective cohort study in a university teaching hospital (2007-2024). (PubMed, Br J Dermatol) - "While younger age, male sex and higher cumulative dose correlated with improved outcomes, these associations were not statistically significant. Further studies with larger cohorts and longer follow-up are needed to refine treatment protocols and optimize patient outcome."

Clinical • Journal • Retrospective data • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology • T Cell Non-Hodgkin Lymphoma